BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-4.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -145.56% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.20 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.33 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.35 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.03 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.71M |
| Free Float | 3.50M |
| Market Capitalization | $12.09M |
| Average Volume (Last 20 Days) | 0.78M |
| Beta (Past 60 Months) | 1.38 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.73% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.42% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |